Eli Lilly shares slid 8.2% last month thanks to tariff tremors and Medicare’s snub of pricey weight-loss drugs. The company’s ...

The day-to-day volatility for the S&P 500 settled down on Monday and Tuesday. But two-thirds of stocks in the U.S. large-cap benchmark index have declined this year, with 220 of the 500 stocks down at ...

Eli Lilly and Company’s LLY shares have lost 8.2% in the past month. A lot of this price decline is due to the global ...

Employment in the U.S. life sciences sector hit a record high in 2024, and more job growth is expected in 2025.

We recently published a list of the 10 High Growth Forever Dividend Stocks to Invest In. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other ...

Pfizer will stop developing an obesity pill that has been closely watched by investors, a severe blow in its efforts to ...

Eli Lilly benefits from rising cash flow and a strong pipeline, yet elevated pricing versus peers limits near-term gains. See ...

Economists around the world are expecting muted U.S. economic growth in the coming quarters, and some indicators suggest the likelihood of a recession has increased in the wake of trade wars.

But this is just the start. GLP-1 drugs (specifically Novo Nordisk’s Ozempic, Rybelsus and Wegovy and Eli Lilly’s Mounjaro ...

“One would expect that companies that pay dividends are more stable and have lower growth rates. As a result, they should rally less in up markets and decline less in down markets. In other words, ...

The decision is a setback for GLP-1 drugmakers, though it's not entirely surprising given the Trump administration’s focus on curbing government spending.